Quantitative Electroencephalography as a Diagnostic Aid for Attention-Deficit/Hyperactivity Disorder, Cognitive Impairment, or Autism Spectrum Disorder

This policy addresses use of quantitative electroencephalography (qEEG)—including theta/beta ratio testing such as the NEBA System—as a diagnostic aid for attention‑deficit/hyperactivity disorder (primarily children and adolescents), cognitive impairment/dementia evaluations, and autism spectrum disorder. However, qEEG-based assessment is considered experimental/investigational and not an established stand‑alone diagnostic tool; coverage is subject to the member’s benefit plan, FDA device controls and required demonstration of clinical validity, reproducibility, and appropriate labeling, and additional clinical evaluation is required before diagnosis or treatment.

"Use of quantitative electroencephalography (qEEG) as a diagnostic aid for attention-deficit/hyperactivity disorder (ADHD)."

Sign up to see full coverage criteria, indications, and limitations.